Suzhou, March 16, 2023 - Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the latest preclinical data from the company's hedgehog inhibitor GT1708F for the treatment of Acute Myeloid Leukemia (AML) has been selected for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting, and the abstract is available on AACR's official website.

The AACR Annual Meeting is the focal point of global cancer research community, gathering the latest advances in cancer science and medicine. This year's AACR annual meeting will be held from April 14-19, 2023, in Orlando, Florida, United States.

GT1708F is a hedgehog signal transduction pathway inhibitor that is under clinical development by Kintor Pharma for the potential treatment of blood cancer and Idiopathic Pulmonary Fibrosis (IPF).

■ Abstract information

Abstract Title: Combination of a clinical stage-hedgehog inhibitor, GT1708 (GT1708F is the salt form of GT1708), improves venetoclax-induced apoptosis by down-regulating MCL-1 proteins in AML cells

Abstract#：4978

Session: Novel Targets and Pathways

Session Time：Tuesday, April 18, 2023, 1:30 PM-5:00 PM, EDT

Acute Myeloid Leukemia (AML) is the third hematological malignancies with the worst relative overall 5-year survival rate (11.7%) in hematological malignancies. The hedgehog (HH)/glioma-associated oncogene homolog (GLI) signaling pathway has been one of the most promising targets for drug discovery and developments for AML. GT1708F was shown to improve ABT-199 (venetoclax)-induced apoptosis by down-regulating MCL-1 proteins in AML cells. GT1708F has been testing in a phase I study in AML patients with previous multiple lines of regimens. GT1708F has been shown to reduce blast counts in three of 13 AML patients treated with higher doses and demonstrated favorite PK and safety profiles. In brief, these results support the clinical development of GT1708F in combination with ABT-199 in AML patients.

Abstract Link: https://www.abstractsonline.com/pp8/#!/10828/presentation/6700

Please refer to the website of AACR for more details.

Attachments

Disclaimer

Kintor Pharmaceutical Ltd. published this content on 16 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 March 2023 10:14:43 UTC.